News Ipsen buys ImCheck, adding mid-stage leukaemia drug Ipsen has agreed to buy ImCheck and its anti-BTN3A antibody for acute myeloid leukaemia in a deal that could be worth up to €1bn.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
